Overview

Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The trial will investigate the influence of hepatic function on the PK of gemigliptin. In an additional treatment period, the PK and safety of multiple dosing of gemigliptin in healthy White subjects will be investigated.
Phase:
Phase 1
Details
Lead Sponsor:
LG Life Sciences